Medical Access and Reimbursement in Kazakhstan

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #; enforcement and penalties are implemented under Kazakhstan’s narcotics legislation and criminal code.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. MDMA and related substituted amphetamines are controlled under Kazakhstan’s lists of narcotic and psychotropic substances. #.

Esketamine (marketed internationally as Spravato) does not appear in Kazakhstan regulatory product lists as an approved, reimbursed psychiatric product for routine outpatient treatment; therefore routine clinical/reimbursed access in psychiatry is not established. Local regulators have recently tightened controls on ketamine-class substances and highlighted the need for regulated circulation of psychoactive medicines in pharmacies and clinics. #; guidance and enforcement actions referencing ketamine as a controlled medicinal/psychotropic substance have been published by Kazakhstan health authorities and regional medical/pharmaceutical oversight bodies. # Given the absence of an identifiable national marketing/registration record for Spravato in Kazakhstan public registries accessible in reviewed sources, esketamine would only be accessible through formal import/registration pathways (if pursued) or within authorised clinical research — not as a reimbursed, routinely available treatment.

Ketamine is a registered medicinal product in Kazakhstan for standard medical indications (primarily general anaesthesia and analgesia) and is included in national formularies and product registries; its manufacture, distribution and clinical use are subject to controlled‑substance regulation and prescription requirements. For example, product registration records indicate ketamine formulations registered in Kazakhstan (registration entry shown with dates and registration number). # National policy has also emphasised strengthening control over ketamine circulation (e.g., Government Decree amendments and Ministry-level communications on tighter oversight of ketamine in pharmacy supply chains). #.

Regulatory/coverage context and psychiatric use nuance:
- Regulatory body: Ministry of Health of the Republic of Kazakhstan and its Medical and Pharmaceutical Control Committee oversee registration, distribution and control of medicinal products and psychotropic substances. #.
- Public reimbursement: Ketamine’s primary registered indications are anaesthesia and analgesia, and publicly funded formularies and procurement processes cover essential anaesthetic medicines; explicit, nationwide reimbursement for ketamine when used off‑label for psychiatric indications (for example, for treatment‑resistant depression via intravenous infusion) is not documented in public reimbursement schedules available in reviewed sources and would typically fall outside routine state psychiatric drug reimbursement unless explicitly adopted by a payer or included in a clinical guideline/procurement list. #.
- Clinical/operational: Medical use requires appropriate controlled‑substance handling (licensed facilities, prescriptions, and recordkeeping). Recent public communications from regional health regulators reference enforcement actions and guidance to pharmacies and hospitals around ketamine’s controlled circulation, indicating regulatory scrutiny. #.

Inference: Ketamine is medically available and registered for anaesthetic/analgesic indications and is controlled in distribution; psychiatric use (IV/infusion for depression) would be off‑label, institution‑dependent, and is unlikely to be covered as a routine reimbursed psychiatric therapy without explicit payer policy or guideline inclusion (no publicly‑available national reimbursement policy for ketamine psychiatric indications was identified in reviewed sources).

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no evidence of an approved medical pathway or reimbursed treatment program involving ibogaine in Kazakhstan. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT or other scheduled tryptamines are controlled; ceremonial or religious use does not constitute legal medical authorization. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline and synthetic phenethylamines are regulated under the national lists. #.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines/2C-series compounds are controlled under Kazakhstan’s narcotics and psychotropic substances lists and fall under enforcement and criminal penalties. #.